We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
-3.14%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$52.8B
AUM Growth
-$1.34B
Cap. Flow
+$1.39B
Cap. Flow %
2.62%
Top 10 Hldgs %
12%
Holding
4,607
New
780
Increased
956
Reduced
789
Closed
1,336

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$532M
2
WFC icon
Wells Fargo
WFC
+$480M
3
V icon
Visa
V
+$435M
4
VZ icon
Verizon
VZ
+$320M
5
AVGO icon
Broadcom
AVGO
+$273M

Sector Composition

Rank Sector Weight
1 Financials 18.66%
2 Technology 16.35%
3 Healthcare 16.13%
4 Consumer Discretionary 11.2%
5 Industrials 7.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ON icon
51
ON Semiconductor
ON
$33.8B
$175M 0.33%
2,801,149
+1,890,073
+207% +$115M
ECL icon
52
Ecolab
ECL
$75.6B
$173M 0.33%
978,684
+974,571
+23,695% +$183M
ALC icon
53
Alcon
ALC
$33.1B
$168M 0.32%
2,100,630
+716,885
+52% +$55.4M
TLT icon
54
CALL
iShares 20+ Year Treasury Bond ETF
TLT
$42.1B
$167M 0.32%
1,265,000
+533,400
+73% +$73.6M
LULU icon
55
lululemon athletica
LULU
$13B
$165M 0.31%
452,969
+181,525
+67% +$59.1M
ES icon
56
Eversource Energy
ES
$28.2B
$162M 0.31%
1,841,669
+1,808,126
+5,390% +$155M
SQM icon
57
Sociedad Química y Minera de Chile
SQM
$19.6B
$156M 0.3%
1,826,730
+54,669
+3% +$3.5M
ENTG icon
58
Entegris
ENTG
$19.7B
$156M 0.3%
1,189,211
+375,917
+46% +$48.3M
ITCI
59
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$154M 0.29%
2,519,764
+131,470
+6% +$6.83M
CLH icon
60
Clean Harbors
CLH
$16.1B
$153M 0.29%
1,367,265
-10,395
-0.8% -$1.03M
MRVL icon
61
Marvell Technology
MRVL
$174B
$152M 0.29%
2,116,456
+1,108,090
+110% +$79.8M
LMT icon
62
Lockheed Martin
LMT
$134B
$150M 0.28%
340,538
+327,561
+2,524% +$133M
GILD icon
63
Gilead Sciences
GILD
$161B
$148M 0.28%
2,490,439
+2,462,555
+8,831% +$157M
LW icon
64
Lamb Weston
LW
$6.82B
$147M 0.28%
2,455,389
-1,095,626
-31% -$68.1M
STE icon
65
Steris
STE
$20.9B
$146M 0.28%
603,738
-535,711
-47% -$124M
NVDA icon
66
NVIDIA
NVDA
$5.01T
$145M 0.27%
5,310,990
-12,027,580
-69% -$302M
A icon
67
Agilent Technologies
A
$39.1B
$143M 0.27%
+1,082,487
New +$149M
RJF icon
68
Raymond James Financial
RJF
$32.5B
$142M 0.27%
1,290,363
+97,168
+8% +$10.3M
MASI
69
DELISTED
Masimo
MASI
$141M 0.27%
968,094
+967,981
+856,620% +$186M
CLF icon
70
Cleveland-Cliffs
CLF
$6.81B
$141M 0.27%
4,369,243
+1,602,593
+58% +$36.5M
MRNA icon
71
Moderna
MRNA
$21.5B
$139M 0.26%
809,135
+763,285
+1,665% +$129M
JWN
72
DELISTED
Nordstrom
JWN
$136M 0.26%
5,020,379
+2,956,367
+143% +$69.2M
HYG icon
73
CALL
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$16.3B
$135M 0.26%
1,640,100
+1,215,900
+287% +$102M
MDB icon
74
MongoDB
MDB
$24B
$134M 0.25%
302,051
+282,946
+1,481% +$111M
GLD icon
75
CALL
SPDR Gold Trust
GLD
$131B
$134M 0.25%
741,000
-177,300
-19% -$31.1M

Similar funds

Marshall Wace's Q1 2022 Portfolio in Review

As of Q1 2022, Marshall Wace held 4,607 positions worth $52.8B, down 2.5% from $54.2B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Marshall Wace's Q1 2022 filing shows 780 new, 956 increased, 789 reduced and 1,336 closed positions. Its largest new stake was Agilent Technologies: 1,082,487 shares worth $143M. The largest sale was Microsoft, an estimated $547M.

By sector, the portfolio is most concentrated in Financials at 19% of assets, up from 16% a quarter earlier, followed by Technology and Healthcare.

  • Marshall Wace's largest Q1 2022 buy was Agilent Technologies: 1,082,487 shares worth $143M.
  • Marshall Wace added most to Merck in Q1 2022, an estimated $532M increase.
  • Marshall Wace's biggest Q1 2022 reduction was Microsoft, cutting an estimated $547M.
  • Marshall Wace fully exited Elevance Health in Q1 2022, selling an estimated $226M.
  • Marshall Wace's ten largest holdings make up 12% of its $52.8B portfolio in Q1 2022.
  • Marshall Wace opened 780 new positions and closed 1,336 in Q1 2022.
  • Marshall Wace's portfolio value fell 2.5% quarter-over-quarter to $52.8B.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.